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Abstract 
 The splicing of pre-mRNA into functional mRNA, carried out by the spliceosome, 
represents a crucial step for the cell's genetic expression. Mutations in some of the 
spliceosome’s components have been identified in several hematological malignancies, 
including myelodysplastic syndromes and acute myeloid leukemia (AML), which could 
constitute a potential therapeutic target to be explored. In this context, we evaluated the 
therapeutic potential of a splicing inhibitor, Pladienolide B (Pla-B), in two erythroleukemia 
cell-lines.  
 K562 and HEL cells were incubated in the absence or presence of increasing 
concentrations of Pla-B in single dose (from 0.25 to 100 nM) and in daily administration (for 
0.5 nM). Cell viability and density were evaluated using the trypan blue method. Cell death 
was determined by optical microscopy (May-Grunwald Giemsa staining) and flow cytometry 
(FC). Cell cycle analysis was evaluated by FC, using a PI/RNAse solution. DNA sequencing 
was performed to assess the presence of SF3B1 mutations in exons 14 and 15. 
 Treatment with Pla-B significantly decreased the viability and proliferation of the 
K562 and HEL cells in a time, concentration and administration schedule dependent manner. 
HEL cells were more sensible to Pla-B than K562 cells (after 72 hours of incubation the IC50 
was 1.5 nM and 25 nM, respectively), which may be due to different cell genetic 
backgrounds. In fact, K562 cells present the BCR-ABL fusion gene and HEL cells the JAK2 
V617F mutation. However, SF3B1 mutations in exons 14 or 15 were not detected in any cell 
model used, suggesting that the observed cytotoxic effect is not dependent on this 
spliceosome mutation. Pla-B induced cell death preferentially by apoptosis and induced also 
an accumulation of cells in the G0/G1 phase of the cell cycle. 
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Our results show that Pla-B induces a cytostatic and cytotoxic effect in K562 and HEL 
cells, suggesting that Pla-B could represent a new therapeutic approach in the treatment of 
erythroleukemia.  
Keywords: Pladienolide B, Splicing inhibitor, SF3B1, AML, Erythroleukemia 
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Resumo 
O splicing de pre-mRNA em mRNA funcional, mediado pelo spliceossoma, representa 
uma etapa fundamental na expressão genética da célula. Nos últimos anos, mutações em 
alguns dos componentes do spliceossoma foram identificadas em várias neoplasias 
hematológicas, incluindo síndromes mielodisplásicos e leucemia mielóide aguda, 
representando alvos terapêuticos por explorar. Neste contexto, avaliámos o potencial 
terapêutico de um inibidor do splicing, Pladienolide B (Pla-B), em duas linhas celulares de 
eritroleucemia.   
As células K562 e HEL foram incubadas na presença ou ausência de concentrações 
crescentes de Pla-B, em dose única (0.25 nM a 100 nM) e dose diária (0.5 nM). A viabilidade 
e a densidade celulares foram avaliadas pelo método de azul tripano. A morte celular foi 
determinada por microscopia óptica (coloração de May-Grunwald Giemsa) e citometria de 
fluxo (FC). A análise do ciclo celular foi realizada por FC, usando uma solução de PI/RNAse. 
Mutações nos exões 14 ou 15 do gene SF3B1 foram pesquisadas através de sequenciação do 
DNA. 
O tratamento das células K562 e HEL com Pla-B reduziu significativamente a 
viabilidade e proliferação celulares, de um modo dependente de tempo, concentração e modo 
de administração do fármaco. As células HEL mostraram-se mais sensíveis ao fármaco do que 
as células K562 (após 72 horas de incubação, o IC50 foi de 1.5 nM e 25 nM, respectivamente), 
o que pode ser devido a diferenças genéticas. De facto, as células K562 apresentam o gene de 
fusão BCR-ABL, enquanto as HEL apresentam a mutação do JAK2 V617F. No entanto, não 
foram encontradas mutações, em nenhum dos modelos, nos exões 14 ou 15 do gene SF3B1, o 
que sugere que o efeito citotóxico observado não é dependente desta mutação. Verificámos 
que o Pla-B induz morte celular preferencialmente por apoptose, bem como induz uma 
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acumulação das células na fase G0/G1 do ciclo celular. Mutações nos exões 14 e 15 do gene 
SF3B1 foram excluídas. 
Os nossos resultados sugerem que o Pla-B apresenta um efeito anti-proliferativo e 
citotóxico em ambas as linhas celulares, e que poderá representar uma nova abordagem 
terapêutica no tratamento da eritroleucemia. 
Palavras-Chaves: Pladienolide B, inibidor do splicing, SF3B1, LMA, eritroleucemia 
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Abbreviations 
AEL : acute eryrholeukemia 
AML: acute myeloid leukemia 
AML-MRC: acute myeloid leukemia with myelodysplasia-related changes 
APC: allophycocyanin 
ATCC: american type culture collection  
ATP: adenosine triphosphate 
AV: annexin V 
CML: chronic myelogenous leukemia 
ddNTP: dideoxy nucleoside triphosphates 
DMSO: Dimethyl sulfoxide 
FAB: french-american-british 
FBS: fetal bovine serum 
FC: flow cytometry 
IC50: half maximal inhibitory concentration  
MDS: myelodysplastic syndrome 
MDS/MPN: myelodysplastic syndrome/myeloproliferative syndrome 
MIF: mean intensity fluorescence 
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mRNA: messenger ribonucleic acid 
PBS: phosphate buffer solution 
PI: propidium iodide 
Pla-B: pladienolide B 
PRPF40B: Pre-mRNA processing factor 40 homolog B 
RNA: ribonucleic acid 
RPMI: roswell park memorial institute 
RUNX1: runt related transcription factor 1 
PCR: polymerase chain reaction 
SEM: standard error of the mean 
SF1: splicing factor 1 
SF3B: splicing factor subunit 3  
SRSF2: serine/arginine-rich splicing factor 2 
snRNA: small nuclear ribonucleic acids 
TET2: ten eleven translocation 2 gene 
U2AF: U2-associated factor 
WHO: world health organization 
ZRSR2: zinc finger, RNA-binding motif and serine/arginine rich 2 
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Introduction 
Splicing is a fundamental cellular process by which the non-coding sequences known 
as introns are removed from pre-mRNA and the flanking exons are ligated to form functional 
mRNA. This complex multistep process is carried out by the spliceosome, a macromolecule 
composed of five small nuclear ribonucleic acids (snRNA) and numerous associated proteins 
(Figure 1) [1]. It starts with the spliceosome assembly phase, with formation of the E (Early) 
complex, which results from the ligation of the U1 snRNP to the 5’ splice site and from the 
U2AF (U2-Associated Factor) to the 3’ splice site and adjacent polypyrimidine tract 
(mediated by the subunits U2AF1 and U2AF2, respectively). This step is followed by an ATP 
dependent alteration in the transcript positioning which brings together the two exons and 
consequently facilitates the ligation of the U2 snRNP to the branch point sequencing, 
generating the A complex. The SF3B1 is the part of this U2 snRNP which mediates the 
binding to the intronic branch point sequence. The B complex is later formed by addition of 
the U4/U5/U6, leading to an ATP dependent conformational rearrangement which constitutes 
a catalytically active C complex, with the resultant release of U2AF, U1 and U4 snRNPs. 
Finally, two transesterifications occur and the intronic sequence is removed, with consequent 
connection of the contiguous exons [2]. 
Somatic mutations interfering with the splicing process have been identified in several 
malignancies, mostly in hematological neoplasms [2]. They were found to be especially 
prevalent in patients presenting with myelodysplastic syndromes (MDS), a heterogeneous 
group of diseases characterized by cell line dysplasia, ineffective hematopoiesis, peripheral 
cytopenias and higher predisposition to acute myeloid leukemia (AML) [2]. The most 
common mutations were found in U2AF1, SRSF2 and SF3B1, the latter being associated with 
the specific phenotype of ringed sideroblasts. These mutations were heterozygous, mutually 
Antitumor activity of splicing inhibitor Pladienolide B in erythroleukemia – a study in cell lines 
10 
 
exclusive and often missense, occurring in specific hotspots for SF3B1 (in exons 14 and 15) 
and SRSF2.  U2AF1 mutations affected exons 2 and 6, which correspond to the 2 zinc finger 
domains of the protein. Interestingly, evidence shows that the mutations did not result in a 
widespread splicing dysfunction, but rather in alterations of the splicing pattern of specific 
genes. For instance, U2AF1 mutations were associated with defective splicing of intron 5 of 
TET2 gene, whereas SF3B1 and SRSF2 mutations affected splicing of RUNX1 gene [3]. 
 
Figure 1. Schematic representation of the pre-mRNA splicing process, from J. Boultwood et al. in [1]. The 
E complex is formed by binding of the U1 snRNP to the 5’ splice site and SF1, SRSF2, ZRSRS2, U2AF35 and 
U2AF65 to the 3’ splice site. The U2 snRNP replaces SF1 and binds to the branch site, forming complex A, and 
aids the binding of U4/U5/U6 snRNP, to form complex B. This brings the two adjacent splice sites together and 
forms complex C, with subsequent intron removal and ligation of the contiguous exons.  
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Given this new genetic insight, over the past few years several substances that target 
the splicing process have been tested as antineoplastic agents in different malignancies, 
including breast, brain, colon, lung, ovarian, renal, gastric and prostate neoplasias in vitro 
[4,5]. Some in vivo studies have also been conducted, both in animal models [4,5] and in 
patients with advanced solid tumors [6], in the context of a phase I study. Between these new 
drugs is Pladienolide B (Pla-B), a twelve-membered macrolide ring, which inhibits the 
splicing process through direct targeting of the SF3B complex [7]. Various studies have 
shown its strong antitumor activity against the previously stated human cancer cell lines, as 
well as in primary cultures, with an IC50 value in a low nanomolar range. Moreover, it has 
been proven to inhibit tumor growth and even induce complete regression in colon and gastric 
human cancer xenograph models in mice [4,5]. Furthermore, since Pla-B has shown a potent 
effect in cell lines resistant to conventional drugs [4] it could be a viable option in the 
treatment of refractory disease. However, to our knowledge, no data are available regarding 
the antineoplastic effect of this drug against hematological malignancies. The fact that 
spliceosome mutations are present in a variety of myeloid malignancies suggests that these 
could play an important role in defining a malignant phenotype. 
Acute erythroleukemia (AEL) is a rare type of AML which consists of a clonal 
proliferation of erythroid precursors and usually also other myeloid precursors in bone 
marrow . Until recently, it was classified as an M6 AML, according to the French-American-
British (FAB) classification system [8]. In 2008, the WHO proposed a new classification, 
where the category of AML with myelodysplasia-related changes (AML-MRC) was 
proposed. This category includes all cases of AML with presence of either morphologic 
evidence of significant multilineage dysplasia, specific MDS–related cytogenetic 
abnormalities, or a history of MDS or a MDS/MPN. Therefore, some AEL cases are now 
classified as AML-MRC. Cases with blasts comprising less than 20% of all cells but more 
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than 50% of erythroid precursors are classified as AEL, if blasts constitute 20% or more of the 
nonerythroid cells. . If blasts constitute less than 20% of nonerythroid cells, the cases are 
classified into various categories of myelodysplastic syndromes (MDS). In a retrospective, 
multi-institutional study of patients with AEL conducted in 2010 [9], the majority of patients 
presented a secondary leukemia, whether with a previous history of MDS, chronic cytopenia 
or therapy-related disease. Furthermore, AEL is frequently accompanied by unfavorable 
cytogenetics.  Another study [10] indicated that the outcome is better for patients treated with 
hypomethylating agents when compared to standard cytarabin based chemotherapy. However, 
the prognosis was still poor, with a median overall survival time of 15.4 months in the 
patients who received azacytidine. Thus, the development of novel drugs for the better 
management of this disease is imperative.  
In this context, we studied the antineoplastic effect of Pladienolide B in two 
erythroleukemia cell lines, the K562 and HEL cells.  We evaluated the effect of this new drug 
in cell growth and viability, and performed a cell death and cell cycle analysis, in order to 
better elucidate the mechanism of action of this drug. In addition, both cell lines were 
screened for the presence of mutations in the SF3B1 gene, to correlate mutation status with 
Pla-B efficacy. 
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Materials and Methods 
Cell culture: In this study we used two different cell lines, K562 and HEL, which were 
purchased from the American Type Culture Collection (ATCC). The K562 cells were 
originally obtained from the pleural effusion of a 53-year-old female with chronic 
myelogenous leukemia (CML) in blast crisis (characterized as erythroleukemia) and bear the 
translocation (9; 22), with consequent presence of the Philadelphia Chromosome [11]. The 
HEL cells were originally obtained from the bone marrow of a 30–year-old caucasian male 
with erythroleukemia and are JAK2-V617F mutated [12]. All cell lines were routinely grown 
in an advanced RPMI-1640 medium (L-glutamine 2 mM, HEPES-Na 25 mM, penicillin 100 
U/mL and Streptomycin 100 µg/mL), supplemented with 5% heat-inactivated fetal bovine 
serum at 37ºC in a humidified atmosphere containing 5% CO2. Cells were cultured at initial 
density of 0.5 x 10
6
 cells/mL for the K562 and 0.4 x 10
6
 cells/mL for the HEL cell line.   
Pladienolide B (Pla-B) was purchased from Santa Cruz Biotechnology (UK) and dissolved in 
DMSO. Both the HEL and K652 cell lines were incubated for 72 hours in the absence and in 
the presence of increasing concentrations of Pla-B, ranging from 0.25 to 100 nM. The drug 
was administered in single dose and for 0.5 nM of Pla-B was also tested a daily administration 
scheme. For flow cytometry and morphological studies was used 2.5 nM of Pla-B. 
Cell viability and density analysis: The K652 and HEL cells viability and density was 
accessed every 24 hours during 72 hours by the trypan blue exclusion method. This method is 
based on the principle that live/viable cells possess intact cell membranes that exclude the 
dye, whereas dead/non-viable cells do not. Briefly, equal volumes of cell suspension and 
trypan blue (Sigma Aldrich) were added, loaded in a hemacytometer and counted under a 
microscope. Cell viability was calculated as the percentage of viable cells whereas cell 
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density was determined by the number of viable cells. The IC50 (drug concentration that 
reduces the viability in 50%) was evaluated by a dose response curve.  
Assessment of cell death: Cell death was evaluated by flow cytometry (FC), using anexin V 
(AV) and propidium iodide (PI) double staining. In apoptotic cells, phosphatidilserine 
migrates from the inner to the outer layer of the cell membrane. In the presence of calcium, 
AV exhibits an affinity for this phospholipid and when associated with a fluorochrome detects 
its redistribution in the cell membrane. In necrotic cells, the membrane becomes permeable 
and molecules such as PI enter the cell and binds to the DNA. Therefore, this assay 
discriminates among viable cells (AV-/PI-), early apoptotic (AV+/PI-), late apoptotic/necrotic 
(AV+/PI+), and necrotic cells (AV-/PI+), as represented in Figure 2. Succinctly, after 48 
hours of incubation, the cells were co-stained with AV-APC (BD Pharmingen) and PI 
(BioLegend) using the manufacturer’s recommendations. The cells were washed with PBS, 
centrifuged at 500g for 5 minutes, resuspended in 100 µL of binding buffer and incubated 
with 5 µL of AV-APC solution and 2.5 µL of PI for 15 minutes in the absence of light. After 
incubation time, cells were diluted in 400 µL of binding buffer and analyzed by FC. Results 
are expressed in % ± SEM of at least three independent experiments. 
Figure 2. Example of a dot plot obtained from a flow cytometry assay. Blue dots represent viable cells, 
green dots represent necrotic cells, red dots represent apoptotic cells and yellow are late apoptotic/necrotic cells. 
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The ApoStat Probe is designed to identify and quantify caspase activity in cells by FC. 
About 1x10
6
 cells were resuspended in 1000 µL of PBS and incubated with 1µg of ApopStat. 
After a 15 min incubation period at 37°C, the cells were washed and resuspended in 400 µL 
of PBS for analyzed by FC. Results are represented in % ± SEM and in MIF (mean 
fluorescence intensity) ± SEM, which represents the mean fluorescence intensity detected in 
cells and is proportional to the number of molecules labeled with the antibody.  
Cell death essays were conducted using a FACSCalibur flow cytometer (Becton 
Dickinson, San Jose, CA) and at least 10.000 events were collected by acquisition using 
CellQuest software (Becton Dickinson, San Jose, CA) and analyzed using Paint-a-Gate 
(Becton Dickinson, San Jose, CA).  
Morphological studies were conducted to evaluate the alterations induce by exposure to Pla-
B. After 48 hours of incubation, the cells were centrifuged at 1000xg for 5 minutes, being the 
supernatant excluded. The pellet was resuspended in 10 µL of FBS. Smears were stained for 3 
minutes with May-Grünwald solution, and then for 15 minutes with Giemsa solution. After 
rinsing with distilled water, cell morphology was analyzed by light microscopy (Nikon 
Eclipse 80i microscope equipped with a Nikon digital camera DXm 1200F). 
Cell cycle analysis: Cell cycle analysis was performed by FC, using PI/RNAse solution 
(Immunostep). As previously said, PI is a fluorescent dye that stains DNA in permeable cells. 
The fluorescence intensity, read by FC, is proportional to the DNA quantity of each cell, 
allowing us to determine the relative proportion of cells in the G0/G1 phase (fewer amount of 
DNA), S phase (coincident with DNA replication) and G2/M phase (double DNA of the 
G0/G1 phase). Given that apoptotic cells undergo the process of DNA fragmentation, these 
cells are represented as an apoptotic peak pre-G1, with the fewest DNA quantity. Briefly, 
after 48 hours of incubation, cells were collected and washed with PBS for 5 min at 1000 xg. 
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The pellet was resuspended in 200 µL of ice cold 70% ethanol solution, during vortex 
agitation, being incubated during 30 min on cold. Then, cells were washed with PBS, 
resuspended in 400 µL of PI/RNase solution and analyzed by FC. A FACSCalibur flow 
cytometer (Becton Dickinson, San Jose, CA) was used and at least 10.000 events were 
collected by acquisition using CellQuest software (Becton Dickinson, San Jose, CA). Results 
were analyzed using Modfit software (Becton Dickinson, San Jose, CA) and are expressed in 
% ± SEM of at least 3 independent experiments.  
Spliceosome mutation detection: The presence or exclusion of mutations on exons 14 and 
15 of the SF3B1 gene was analyzed using the Sanger sequencing method. This method allows 
DNA sequencing by selective incorporation of chain terminating ddNTP by a DNA 
polymerase during in vitro DNA replication. Briefly, the SF3B1 fragment was amplified using 
PCR primers flanking exons 14 and 15 (Table 1).  
 
 Table 1. Sequences of primers used in the present study  
 
PCR was performed in a reaction volume of 24 µl containing 2 µl of genomic DNA, 0.2µl of 
Taq polymerase 5U/µl, 2.5 µl of Taq PCR Buffer, 0.5 µl of dNTP (10 mM each) and 0.5 µl of 
each of the primers. The PCR program was as follows: initial denaturation at 95 °C for 3 
minutes and 34 cycles of amplification at 95 °C for 45 seconds, 60°C or 54ºC (for exon 14 or 
Primer Sequence (5’-3’) Fragment Size (bp) 
SF3B1 exon 14F CCAACTCATGACTGTCCTTTCTT 
362 
SF3B1 exon 14R GGGCAACATAGTAAGACCCTGT 
SF3B1 exon 15F TTGGGGCATAGTTAAAACCTG 
261 
SF3B1 exon 15R AATCAAAAGGTAATTGGTGGA 
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15, respectively) for 45 seconds and 72 °C for 45 seconds. A final extension step at 72 °C for 
10 minutes was performed. After purification of the amplicons using the ExoSAP-IT enzyme, 
according to the manufacturer’s protocol, cycle sequencing was performed using a Big Dye 
Terminator v3.1 Cycle Sequencing kit, following the manufacturer’s instructions. The thermal 
cycling profile was as follows: initial denaturation at 94 °C for 3 minutes and 24 rounds of 
amplification at 96 °C for 10 seconds, 50°C for 5 seconds and 60 °C for 1 minute and 45 
seconds. The products of the sequencing reactions were purified using DyeEx 2.0 columns 
and read in an optic microplate. Sequencing data were analyzed using Chromas software. 
 
4.6 Statistical analysis: Statistical analysis was performed using the GraphPad Prism 
software. Student’s t test, analysis of variance, Dunnett’s test and Tuckey test were used to 
compare the different groups. A significance level of p < 0.05 was considered statistically 
significant. Results are expressed in mean ± SEM of the number of independent experiments 
indicated in the figure legend.  
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Results 
Anti-tumoral activity of Pladienolide-B 
We studied the influence of Pla-B in cell density and viability in two erythroleukemia 
cell lines, K562 and HEL, in single dose administration (Figure 3). Pla-B induces a decrease 
of cell density and cell viability in a time- and dose dependent manner, for both cell lines. For 
the K562 cell line, the exposure to Pla-B in concentrations higher than 2.5 nM induces a 
significant decrease of cell density when comparing with untreated cells. The same significant 
decrease was observed for HEL cells (Figure 3A), revealing the cytostatic effect of Pla-B. In 
terms of cell viability, we also observed a significant reduction following Pla-B treatment. 
However, this effect is cell line dependent, being the half maximal inhibitory concentration 
(IC50) after 72 hours of incubation of 25 nM and 1.5 nM for K562 and HEL cells, 
respectively. Comparing the cytotoxic effect between cell lines, the HEL cell line revealed an 
IC50 15 times lower than K562 cells. 
 
               
A 
 
* * 
Antitumor activity of splicing inhibitor Pladienolide B in erythroleukemia – a study in cell lines 
19 
 
         
Figure 3. Dose-response curves of Pla-B in K562 and HEL cell lines. Cells were incubated in a density of 0.5 
and 0.4 x 10
6
 cells/mL, respectively, for 72 hours, in the absence and presence of increasing concentrations of 
Pla-B. Cell density (A) and viability (B) were established by the trypan blue method, as previously described in 
material and methods. Cell viability is expressed in cell percentage, normalized to control. Data are expressed as 
mean ± SEM obtained from at least 5 independent experiments. * p<0.05 
 
To assess if the frequency of administration influences the cytostatic and cytotoxic 
effect of Pla-B, a daily administration scheme was tested using the concentration of 0.5 nM 
(Figure 4). A daily administration of 0.5 nM was compared with 1.5 nM of Pla-B at single 
dose, since this corresponds to the cumulative dose at the end of 72 hours. The daily 
administration of Pla-B reveals to be more effective in the reduction of cell density and cell 
viability than the administration of 1.5 nM at single dose, especially in the HEL cells. After 
72 hours of exposure, the daily dose induced an additional reduction of 15% and 45% in K562 
and HEL cells viability, respectively, when compared to the single dose. The differences in 
cell viability induced by the diferent schemes of drug adminitration were statistical 
significant.  
* 
B 
* 
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Figure 4. Dose response curves for daily administration of Pla-B in K562 and HEL cell lines. Cells were 
incubated in a density of 0.5 and 0.4 x 10
6
 cells/mL, respectively, for 72 hours, in the absence (control) and 
presence Pla-B, in single or daily administration (#). Cell density (A) and viability (B) were established by the 
trypan blue method, as previously described. Cell viability is expressed in cell percentage, normalized to control. 
Data are expressed as mean ± SEM obtained from at least 5 independent experiments. * p<0.05 comparing with 
1.5nM of Pla-B at single dose. 
Cell death analysis 
We analyzed the cell death induce by Pla-B using Annexin V/PI double staining and 
by optical microscopy. As represented in figure 4, the exposure to 2.5 nM of Pla-B results in a 
significant reduction of viable cells with a significant increase of cells in early apoptosis. The 
cell death induced was mainly mediated by apoptosis, but in case of HEL cells, we also 
observed significant differences in percentage of cells in necrosis.  
A 
B 
* 
* 
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Figure 5. Cell death analysis induced by Pla-B in K562 and HEL cell lines using flow cytometry. Cells were 
incubated in a density of 0.5 and 0.4 x 10
6
 cells/mL, respectively, for 48 hours, in the absence (control) or 
presence of 2.5nM of Pla-B. Cell death was detected by annexin V/ propidium iodide staining, analyzed by flow 
cytometry. Data are expressed in percentage (%) and represent mean ± SEM of at least 3 independent 
determinations. * p<0.05, ** p<0.01, *** p<0.001. 
In agreement with flow cytometry analysis, the morphological evaluation showed 
typical alterations of cell death mediated by apoptosis in both cell lines. After treatment with 
Pla-B it was possible to observe blebbing, cell shrinkage, nuclear fragmentation and 
chromatin condensation, confirming apoptosis (Figure 6). In the HEL cell line, we also 
observed cells with permeable membrane and intact nucleus characteristic of necrosis, 
revealing the activation of both cell death mechanisms.  
      
      
HEL 
 
K562 
 
 
*** 
*** 
** ** 
** 
* 
A 
B 
Control 2.5 nM Pla-B 
Control 2.5 nM Pla-B 
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Figure 6. Cell morphological analysis by optical microscopy . K562 and HEL cells were incubated in a 
density of 0.5 and 0.4 x 10
6
 cells/mL, respectively for the K562 (A) and HEL (B) cells, for 48 hours, in the 
absence (control) or presence of 2.5 nM of Pla-B and stained using a May-Grünwald-Giemsa method. The cells 
were analyzed by light microscopy (amplification 100x).   
 
We also analyzed if cell death induced by Pla-B was mediated by caspases activation 
(Figure 7). Treatment with Pla-B induced an increase in percentage of cells with activated 
caspases (of 13% for the K562 cells and 30% for the HEL cells, represented in Figure 7A) 
and in the expression level of caspases (of 5% in the HEL cells, represented in Figure 7B), 
being more pronounced in HEL cells. The differences in percentage of cells were statistical 
significant for HEL cell line. 
 
 Figure 7. Evaluation of caspases expression levels in K562 and HEL cells treated with Pla-B by flow 
cytometry. Cells were incubated in a density of 0.5 and 0.4 x 10
6
 cells/mL, respectively, for 48 hours, in the 
absence (control) or presence of 2.5nM of Pla-B. Caspases expression levels were analyzed using the ApoStat 
probe. Results are expressed in percentage of cells positive (A) and in MIF (B) and represent the mean ± SEM 
of at least 3 independent experiments. ** p<0.01 
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A B 
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Cell cycle analysis 
Besides the confirmed cytotoxic effect induced by Pla-B, to confirm the cytostatic effect, 
we analyzed the effect on cell cycle progression by FC using a PI/RNAse. As represented in 
Figure 8, Pla-B induced a significant arrest in the G0/G1 phase in both cell lines, when 
compared with untreated cells (respectively, 44±1.9% vs 37±1% in K562 cells and 63±0.9% 
vs 35±2.1% in HEL cells). Additionally, by the same technique it was detected the presence 
of an apoptotic peak (pre-G1), corresponding to DNA fragmentation typical of apoptotic cells.  
 
Figure 8. Cell cycle distribution of K562 and HEL cells after Pla-B treatment. Cells were incubated in a 
density of 0.5 and 0.4 x 10
6
 cells/mL, respectively, for 48 hours, in the absence (control) or presence of 2.5 nM 
of Pla-B. Cell cycle distribution was detected using PI/RNAse by flow cytometry. Data are expressed as 
percentage of cells in G0/G1 phase, S phase, G2/M phase and apoptotic peak and represent mean ± SEM 
obtained from at least 3 independent experiments. * p<0.05, ** p<0.01, *** p<0.001. 
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SF3B1 mutation analysis:  
The mutational status of SF3B1 could influence the response levels of cells to Pla-B. 
Thus, using the previously described DNA sequencing method, we searched for mutations in 
exons 14 and exon 15 of the SF3B1 gene in both cell lines. For our in vitro models, we did not 
find any mutations in these two exons. Particularly, no substitutions were revealed in 
positions H662D or K700E, respectively. 
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Discussion and Conclusion  
In this study, we evaluated the therapeutic efficacy of Pladienolide B (Pla-B), a 
splicing inhibitor that specifically targets the ribonucleoprotein complex SF3B. By impairing 
the binding of the spliceosome to the branch sequence, it leads to a splicing dysfunction that 
results in an accumulation of un-spliced mRNA in the cell and consequently in a reduction of 
cell viability [7, 13]. Nevertheless, its mechanism of action is still not fully understood. As 
mutations in spliceosome components are extremely prevalent in myeloid neoplasias [3], this 
drug could represent a new therapeutic target in the treatment of such diseases.  
Our study shows that Pla-B presents a cytotoxic and a cytostatic effect against 
erythroleukemia cell lines in a time, dose and administration scheme dependent manner. 
Induction of cell death was mainly mediated by apoptosis, with activation of caspases. These 
results were in accordance with the experimental study conducted by Sato et al. in gastric 
cancer cell lines, which reveal the activation of apoptotic cell death [5]. We verified that Pla-
B induces an accumulation of cells in the G0/G1 phase, reflecting the anti-proliferative action 
of this drug. A previous study conducted by Mizui et al. in WiDr cells had shown a 
preferential arrest in G1 phase after treatment with Pla-B, but also in the G2/M-phase, in a 
time dependent manner [4].  
The administration scheme has been explored with attempt to minimize the side 
effects of anti-cancer agents. We analyzed two different administration schemes, namely the 
single dose administration and the small daily dose administration. Our results show that the 
daily dose administration of 0.5 nM of Pla-B appears to have more efficacy in both cell lines 
when compared with 1.5 nM at single dose, since it induces a higher cytotoxicity. Daily 
administration scheme could constitute a valid option to reduce the potential side effects of 
Pla-B.  
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Interestingly, Pladienolide B also presented a cell type dependent effect. In fact, HEL 
cells were much more sensitive to Pla-B than K562 cells, with an IC50 at 72 hours of exposure 
of 1.5 nM vs 25 nM, respectively. Further studies are needed to disclose the exact reason by 
which this phenomenon occurs; however, several differences between these two cell lines can 
potentially contribute to the differential response.  
Firstly, although both K562 and HEL are erythroleukemia cell lines, they have a 
different origin and genetic background. As previously described, K562 cells were first 
obtained from a patient with a CML in blast crisis, and present the translocation between 
chromosomes 9 and 21, that originates Philadelphia chromosome and the fusion gene BCR-
ABL [11]. The HEL cell line, on the other hand, was obtained from a patient with an 
erythroleukemia, who had previously received treatment for a Hodgkin Lymphoma, and 
present the JAK2-V617F mutation [12]. These genetic differences may contribute to the 
different drug-responses. In fact, the presence of the BCR-ABL fusion gene has been 
associated with changes in the expression of proteins involved in alternative pre-mRNA 
splicing, a process which greatly diversifies the transcriptome and which is thought to 
contribute to the oncogenic processes. [14] Additionally,  the BRC-ABL 
p210
 oncoprotein has 
been shown to increase the expression of multiple genes involved in pre-mRNA splicing [14]. 
These aberrances in the splicing process can lead to important cell dysfunction, with a 
considerable effect in the regulation of cell proliferation and apoptosis [15]. Thus, it would be 
necessary to study the splicing function of the K562 cells in order to better understand the 
lower drug-sensitivity and if response is correlated with previous splicing dysfunction. 
Several authors have also hypothesized that cells may react differently to Pla-B 
according to the presence or absence of different splicing factor mutations [1,2,16,18]. In the 
present study, only exons 14 and 15 of gene SF3B1 were screened for mutations. As stated in 
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the results section, no mutations were found in the K562 or the HEL cell lines in neither exon. 
However, we did not exclude other mutations in the same or in a different gene. The possible 
mutation in other point may also contribute to the different response levels. H662D (C>G) 
and K700E (A>G) mutations in exons 14 and 15, respectively, have been described as 
hotspots in SF3B1 gene. Even though these mutations are between the most frequents in 
hematological neoplasias [16], numerous other mutations have been identified, both in SF3B1 
and in other splicing related genes. Particularly, the mutation R1074H in SF3B1 gene has 
been associated with resistance to Pladienolide B in colorectal carcinoma cells in vitro [7]. 
The mutation confers resistance since it impairs the binding of Pla-B to the target [7]. 
However, a mutation in this residue has so far not been detected in patients [2].  
Other mutated genes which affect splicing that have been identified in myeloid 
neoplasias may also influence the efficacy of drugs that target this process. These include 
mutations in genes SRSF2, U2AF1, ZRSR2, SF3A1, U2AF2, SF1 and PRPF40B [16]. 
Therefore, and given the high occurrence of mutations affecting these genes in myeloid 
neoplasias [1,17], we cannot exclude their existence in our models. Nevertheless, it is 
important to realize that even though the presence of a mutation may explain a different 
response to the drug, the cause-effect mechanism is not linear or well understood. In fact, it is 
not yet well established whether splicing mutations represent a gain or loss of function, 
although the presence of hot spots and the absence of nonsense or frameshift changes suggest 
that the vast majority are gain of function/neomorphic mutations [1]. Hypothetically, in the 
presence of a gain of function/neomorphic mutation, the use of specific spliceosome inhibitors 
may allow a preferential targeting of the mutant phenotype. Moreover, since splicing factor 
mutations appear to be mostly heterozygous [3], disruption of the remaining allele using 
splicing inhibitors may induce preferential killing of the mutant cells and, eventually, spare 
normal cells. Additionally, it has been proposed that these mutations may result in aberrant 
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alternative splicing, in which case the splicing inhibitor may inhibit the gain of function effect 
of the mutation and restore a normal phenotype [18]. On the other hand, in loss of function 
mutations/dominant-negative effect, the use of splicing inhibitors may result in dysfunction of 
the normal allele, with worsening of the phenotype [2]. Therefore, not only is it important to 
identify the mutations, but also to better characterize their effect, in order to improve our 
understanding and prediction of drug response.  
Moreover, a study conducted in gastric cell lines using a Pla-B derivative associated a 
higher expression of cell cycle proteins, such as cyclin E and p16, with higher sensitivity to 
this drug [5]. The authors suggest that these molecules could be used as a biological 
biomarkers in the future, although a more profound analysis in needed [5]. Therefore, 
differences in the expression of these molecules in our cell lines should be tested in a 
posterior study to clarify the different sensitivity to Pla-B. 
Undoubtedly, further studies are needed to clarify the mechanism of action of Pla-B, 
as well as its potential role in the treatment of hematological malignancies. In particular, 
understanding the reason why these two cell lines respond differently in the presence of the 
drug may help to understand the mechanism of action of Pla-B, as well as the profile of 
patients which may benefit from this treatment.  
In conclusion, Pladienolide-B shows a high antitumor activity against HEL and K562 
cell lines, inducing cell death preferentially by apoptosis and a G0/G1 cell cycle arrest. Even 
though further elucidations are needed, Pla-B most certainly represents a promising new 
approach in the treatment of erythroleukemia. 
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